Outcome and Cost Analysis of Induction Immunosuppression With IL2Mab or ATG in DCD Kidney Transplants

Transplantation - Published Ahead-of-Print Outcome and Cost Analysis of Induction Immunosuppression With IL2Mab or ATG in DCD Kidney Transplants

Background: Kidney transplantation from DCD now represents a significant part of the overall transplant activity in the UK. Outcome of different induction immunosuppression regimes and related cost benefit analysis has been reported by very few studies. This is a single centre study on frequency-matched patients who received a DCD kidney transplant between August 2007 and August 2009. Methods: Data on 45 patients divided in 2 groups were collected prospectively and analyzed retrospectively. Group A (24 patients) received IL2Mab and Group B (21 patients) ATG as induction immunosuppression. Patient and graft survival were similar in both groups. Results: In the ATG-induced group, there was a significant lower rate of DGF, BPAR, and infections requiring readmission. A cost analysis was performed including all immunosuppression-related costs, and it has shown remarkable savings in the ATG-induced group. Conclusion: Considering that the number of DCD kidney transplants is destined to rise in the UK, we believe that ATG is a valid option to continue optimizing outcomes of DCD kidney transplant. In our experience, ATG proved to be safe, effective, and contributed to significant cost savings. (C) 2014 by Lippincott Williams & Wilkins


http://pdfs.journals.lww.com/transplantjournal/9000/00000/Outcome_and_Cost_Analysis_of_Induction.98285.pdf

Sent with Reeder

Enviado desde mi iPhone